The National Polyp Study at 40: challenges then and now

Sidney J. Winawer; Ann G. Zauber; Michael J. O'Brien; Joseph Geenen; Jerome D. Waye

doi:10.1016/j.gie.2020.09.044

The National Polyp Study at 40: challenges then and now

Sidney J. Winawer, Ann G. Zauber, Michael J. O'Brien, Joseph Geenen, Jerome D. Waye

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Original language	English
Pages (from-to)	720-726
Number of pages	7
Journal	Gastrointestinal Endoscopy
Volume	93
Issue number	3
DOIs	https://doi.org/10.1016/j.gie.2020.09.044
State	Published - Mar 2021

Access to Document

10.1016/j.gie.2020.09.044

Cite this

@article{0d5a9ad8f3824c459df69ea500c32286,

title = "The National Polyp Study at 40: challenges then and now",

author = "Winawer, {Sidney J.} and Zauber, {Ann G.} and O'Brien, {Michael J.} and Joseph Geenen and Waye, {Jerome D.}",

note = "Funding Information: The project described was supported by the National Cancer Institute of the National Institute of Health grant no. P30 CA 008748 (Dr Winawer and Dr Zauber), U01 CA 199335 as part of the Cancer Intervention and Surveillance Network (CISNET) (Dr Zauber), R01 CA 26852 (all authors), and R01 CA 46940 (all authors). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or National Institutes of Health. We acknowledge the institutional centers{\textquoteright} Principal Investigators who made this trial possible: John H. Bond, MD, Walter Hogan, MD, Joel F. Panish, MD, Melvin Shapiro, MD, Frederick Ackroyd, MD; Pathology Review: Leonard S. Gottlieb, MD, Stephen S. Sternberg, MD, Edward T. Stewart, MD (Radiology PI), and Martin Fleisher, PhD (FOBT Laboratory PI). We also thank the patients who participated in this study and the research and clinical staff who managed the study. Funding Information: This is a 40-year perspective of the National Polyp Study (NPS), a randomized clinical trial (RCT) sponsored by the American Society for Gastrointestinal Endoscopy, American Gastroenterology Association, and American College of Gastroenterology and funded by the National Cancer Institute with conceptualization and planning starting in 1977 and accrual beginning in 1980. We review how we approached challenges presented by the introduction of colonoscopy and polypectomy, how these findings influenced clinical practice and public health, and how the NPS model was used to address new challenges. Details of the NPS concepts, design, results, and discussion may be obtained from our previously published studies as cited in the references. 1-9 The NPS was an RCT of the timing of surveillance intervals after colonoscopic polypectomy. It also addressed colorectal cancer (CRC) incidence and mortality reduction, familial risk for CRC, use of advanced adenomas as a CRC surrogate, and implications of flat and serrated lesions. Funding Information: The project described was supported by the National Cancer Institute of the National Institute of Health grant no. P30 CA 008748 (Dr Winawer and Dr Zauber), U01 CA 199335 as part of the Cancer Intervention and Surveillance Network (CISNET) (Dr Zauber), R01 CA 26852 (all authors), and R01 CA 46940 (all authors). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or National Institutes of Health. We acknowledge the institutional centers? Principal Investigators who made this trial possible: John H. Bond, MD, Walter Hogan, MD, Joel F. Panish, MD, Melvin Shapiro, MD, Frederick Ackroyd, MD; Pathology Review: Leonard S. Gottlieb, MD, Stephen S. Sternberg, MD, Edward T. Stewart, MD (Radiology PI), and Martin Fleisher, PhD (FOBT Laboratory PI). We also thank the patients who participated in this study and the research and clinical staff who managed the study. DISCLOSURE: All authors disclosed no financial relationships. Research support for this study was provided by the National Cancer Institute of the National Institute of Health (Dr Winawer and Dr Zauber), P30 CA008748, U01 CA 199335 as part of the Cancer Intervention and Surveillance Modeling Network (CISNET) (Dr Zauber), R01 CA 26852 National Cancer Institute of the National Institute of Health (Dr Winawer, Dr Zauber, Dr O'Brien, Dr Waye, and Dr Geenen), and R01 CA 46940 National Cancer Institute of the National Institute of Health (Dr Winawer, Dr Zauber, Dr O'Brien, Dr Waye, and Dr Geenen). Funding Information: DISCLOSURE: All authors disclosed no financial relationships. Research support for this study was provided by the National Cancer Institute of the National Institute of Health (Dr Winawer and Dr Zauber), P30 CA008748, U01 CA 199335 as part of the Cancer Intervention and Surveillance Modeling Network (CISNET) (Dr Zauber), R01 CA 26852 National Cancer Institute of the National Institute of Health (Dr Winawer, Dr Zauber, Dr O{\textquoteright}Brien, Dr Waye, and Dr Geenen), and R01 CA 46940 National Cancer Institute of the National Institute of Health (Dr Winawer, Dr Zauber, Dr O{\textquoteright}Brien, Dr Waye, and Dr Geenen). ",

year = "2021",

month = mar,

doi = "10.1016/j.gie.2020.09.044",

language = "English",

volume = "93",

pages = "720--726",

journal = "Gastrointestinal Endoscopy",

issn = "0016-5107",

publisher = "Mosby Inc.",

number = "3",

}

TY - JOUR

T1 - The National Polyp Study at 40

T2 - challenges then and now

AU - Winawer, Sidney J.

AU - Zauber, Ann G.

AU - O'Brien, Michael J.

AU - Geenen, Joseph

AU - Waye, Jerome D.

N1 - Funding Information: The project described was supported by the National Cancer Institute of the National Institute of Health grant no. P30 CA 008748 (Dr Winawer and Dr Zauber), U01 CA 199335 as part of the Cancer Intervention and Surveillance Network (CISNET) (Dr Zauber), R01 CA 26852 (all authors), and R01 CA 46940 (all authors). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or National Institutes of Health. We acknowledge the institutional centers’ Principal Investigators who made this trial possible: John H. Bond, MD, Walter Hogan, MD, Joel F. Panish, MD, Melvin Shapiro, MD, Frederick Ackroyd, MD; Pathology Review: Leonard S. Gottlieb, MD, Stephen S. Sternberg, MD, Edward T. Stewart, MD (Radiology PI), and Martin Fleisher, PhD (FOBT Laboratory PI). We also thank the patients who participated in this study and the research and clinical staff who managed the study. Funding Information: This is a 40-year perspective of the National Polyp Study (NPS), a randomized clinical trial (RCT) sponsored by the American Society for Gastrointestinal Endoscopy, American Gastroenterology Association, and American College of Gastroenterology and funded by the National Cancer Institute with conceptualization and planning starting in 1977 and accrual beginning in 1980. We review how we approached challenges presented by the introduction of colonoscopy and polypectomy, how these findings influenced clinical practice and public health, and how the NPS model was used to address new challenges. Details of the NPS concepts, design, results, and discussion may be obtained from our previously published studies as cited in the references. 1-9 The NPS was an RCT of the timing of surveillance intervals after colonoscopic polypectomy. It also addressed colorectal cancer (CRC) incidence and mortality reduction, familial risk for CRC, use of advanced adenomas as a CRC surrogate, and implications of flat and serrated lesions. Funding Information: The project described was supported by the National Cancer Institute of the National Institute of Health grant no. P30 CA 008748 (Dr Winawer and Dr Zauber), U01 CA 199335 as part of the Cancer Intervention and Surveillance Network (CISNET) (Dr Zauber), R01 CA 26852 (all authors), and R01 CA 46940 (all authors). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or National Institutes of Health. We acknowledge the institutional centers? Principal Investigators who made this trial possible: John H. Bond, MD, Walter Hogan, MD, Joel F. Panish, MD, Melvin Shapiro, MD, Frederick Ackroyd, MD; Pathology Review: Leonard S. Gottlieb, MD, Stephen S. Sternberg, MD, Edward T. Stewart, MD (Radiology PI), and Martin Fleisher, PhD (FOBT Laboratory PI). We also thank the patients who participated in this study and the research and clinical staff who managed the study. DISCLOSURE: All authors disclosed no financial relationships. Research support for this study was provided by the National Cancer Institute of the National Institute of Health (Dr Winawer and Dr Zauber), P30 CA008748, U01 CA 199335 as part of the Cancer Intervention and Surveillance Modeling Network (CISNET) (Dr Zauber), R01 CA 26852 National Cancer Institute of the National Institute of Health (Dr Winawer, Dr Zauber, Dr O'Brien, Dr Waye, and Dr Geenen), and R01 CA 46940 National Cancer Institute of the National Institute of Health (Dr Winawer, Dr Zauber, Dr O'Brien, Dr Waye, and Dr Geenen). Funding Information: DISCLOSURE: All authors disclosed no financial relationships. Research support for this study was provided by the National Cancer Institute of the National Institute of Health (Dr Winawer and Dr Zauber), P30 CA008748, U01 CA 199335 as part of the Cancer Intervention and Surveillance Modeling Network (CISNET) (Dr Zauber), R01 CA 26852 National Cancer Institute of the National Institute of Health (Dr Winawer, Dr Zauber, Dr O’Brien, Dr Waye, and Dr Geenen), and R01 CA 46940 National Cancer Institute of the National Institute of Health (Dr Winawer, Dr Zauber, Dr O’Brien, Dr Waye, and Dr Geenen).

PY - 2021/3

Y1 - 2021/3

UR - http://www.scopus.com/inward/record.url?scp=85097110641&partnerID=8YFLogxK

U2 - 10.1016/j.gie.2020.09.044

DO - 10.1016/j.gie.2020.09.044

M3 - Article

C2 - 33010298

AN - SCOPUS:85097110641

VL - 93

SP - 720

EP - 726

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

IS - 3

ER -